Esomeprazole

CLINICAL USE

Gastric acid suppression

DOSE IN NORMAL RENAL FUNCTION

20–40 mg dailyZollinger-Ellison syndrome: 80–160 mg daily (doses >80 mg given in divided doses)

PHARMACOKINETICS

Molecular weight :345.4

%Protein binding :97

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :0.22

half-life – normal/ESRD (hrs) :1.3/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anticoagulants: effect of coumarins possibly enhanced

Anti-epileptics: effects of phenytoin enhanced

Antivirals: reduced atazanavir concentration – avoid concomitant use

ADMINISTRATION

Reconstition

5 mL sodium chloride 0.9%

Route

Oral, IV

Rate of Administration

Bolus: over 3 minutes Infusion: 10–30 minutes

Comments

Dilute with up to 100 mL sodium chloride 0.9%

OTHER INFORMATION

Can be dispersed in half a glass of non-carbonated water. Stir well until it disintegrates; the liquid with pellets should be drunk immediately or within 30 minutes of preparation. The glass should then be rinsed with water which should also be drunkDo not crush or chew

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home